Literature DB >> 889712

Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release.

D Heiden, C H Mielke, R Rodvien.   

Abstract

Heparin was administered to 34 normal subjects by intravenous injection (100 mu/kg) and the template bleeding time was significantly increased both 10 min and 120 min following injection. Before heparin the bleeding time was 5-3 +/- 1.0 min (mean +/- 1 SD); 10 min after injection it was 9.8 +/- 5.6 min (P less than 0.001); and 120 min after injection it was 7.2 +/- 3.9 min (P less than 0.001). Increases in the bleeding time were unrelated to changes in platelet count, and independent of heparin's effect on plasma coagulation. In blood drawn 10 min and 120 min following heparin injection, there was significantly less [14C]5-HT released from platelet-rich plasma (PRP) in response to collagen, 0.41 mM epinephrine and 8 micron ADP, although in vitro addition of heparin (0.1 mu/ml, 0.5 mu/ml and 2.5 mu/ml) to baseline PRP of three subjects did not depress [14C]5-HT release. Our experiments suggest that intravenous administration of a therapeutic dose of heparin can cause a significant reversible inpairment of platelet haemostatic properties, possibly by an indirect mechanism.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 889712     DOI: 10.1111/j.1365-2141.1977.tb00666.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.

Authors:  Richard C Becker; Kenneth W Mahaffey; Hongqiu Yang; A J Marian; Mark I Furman; A Michael Lincoff; Stanley L Hazen; John L Petersen; Craig J Reist; Neal S Kleiman
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

3.  Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.

Authors:  M Sobel; P M McNeill; P L Carlson; J C Kermode; B Adelman; R Conroy; D Marques
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

4.  Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

Authors:  D P Mikhailidis; V A Fonseca; M A Barradas; J Y Jeremy; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 5.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

6.  "Haemostasis time", a modified bleeding time test and its comparison with the Duke and Ivy/template bleeding times. I. Normal values, application in thrombocytopenic patients and evaluation of heparin and aspirin effects.

Authors:  H Janzarik; S Remy; S Morell; W Pabst
Journal:  Blut       Date:  1986-06

Review 7.  Intravenous lipids for preterm infants: a review.

Authors:  Ghassan Sa Salama; Mahmmoud Af Kaabneh; Mai N Almasaeed; Mohammad Ia Alquran
Journal:  Clin Med Insights Pediatr       Date:  2015-02-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.